Navigation Links
Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Date:10/5/2010

. Studies to determine whether Aranesp increases mortality or decreases progression-free/recurrence-free survival are ongoing.

  • Aranesp is not indicated for use in patients receiving hormonal agents, therapeutic biologic products, or radiotherapy unless receiving concomitant myelosuppressive chemotherapy.
  • Aranesp is not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure due to the absence of studies that adequately characterize the impact of Aranesp on progression-free and overall survival.
  • Aranesp use has not been demonstrated in controlled clinical trials to improve symptoms of anemia, quality of life, fatigue, or patient well-being.

  • WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE AND INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCECancer:

  • ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers.
  • To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusion.
  • Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense Aranesp, EPOGEN® or PROCRIT® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit http://www.esa-apprise.com/ or call 1-866-284-8089 for further assistance.
  • Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.
  • ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.
  • Discontinue following the completion of a chemotherapy course.
  • ESAs are contraindicated in patients with uncontrolled
    '/>"/>

  • SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
    2. Medarex to Receive Milestone Payment from Amgen
    3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
    4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
    5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
    6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
    7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
    8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
    9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
    10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
    11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
    (Date:9/17/2014)... , September 17, 2014 According ... by Component (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU), ... & Wellness), and by Geography - Global Forecast to ... electronics market is expected to reach $56.50 Billion by ... to 2020. Browse 235 market data Tables ...
    (Date:9/17/2014)... CITY, Utah , Sept. 17, 2014 /PRNewswire/ ... an exclusive global licensing and collaboration agreement with ... and commercialize NuView,s investigative genomic-based diagnostic biomarker to ... agreement also includes all other future diagnostic-imaging applications. ... for in-vivo therapeutic delivery and in-vitro urine screen ...
    Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5
    ... WORCESTER, Mass. and TORONTO, May 17, 2012  Generex ... today that new members have joined the Scientific ... Express, Inc. for the company,s AE37 breast cancer ... N. Hortobagyi, MD, FACP (University of Texas MD ...
    ... TUCSON, Ariz., May 17, 2012 SynCardia Systems, Inc. ... only FDA, Health Canada and CE (Europe) approved Total ... March 31, 2012, due in part to Certified Centers ... SynCardia temporary Total Artificial Heart . ...
    Cached Medicine Technology:Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 2Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 3Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 4SynCardia Posts Record Revenue and Profit in Q1 2012 2SynCardia Posts Record Revenue and Profit in Q1 2012 3
    (Date:9/17/2014)... News) -- Managing diabetes, quitting smoking, controlling high blood ... the risk for dementia -- even late in life, ... Report 2014, commissioned by Alzheimer,s Disease International, revealed that ... percent. The study noted that obesity and an inactive ... as high blood pressure. The researchers suggested ...
    (Date:9/17/2014)... an analysis of genetic information among more than 87,000 ... found 23 new genetic variants common differences in ... for prostate cancer. The so-called "meta-analysis," believed to be ... mutations among men in a broad array of ethnic ... ancestry. , The meta-analysis combined information from smaller studies, ...
    (Date:9/17/2014)... In a country where 77% of inhabitants ... basis, how can Americans find healthy and fulfilling ways ... Challenge , a 5-day interactive journey to putting stress ... From September 29th – October 3rd, the Hyland’s Stress ... specific topics that promote natural solutions for managing stress. ...
    (Date:9/17/2014)... that patients with human papillomavirus (HPV) the ... and neck cancer positive oropharyngeal cancer see ... post-radiation neck dissection than those with HPV-negative oropharyngeal ... findings at the American Society for Radiation Oncology,s ... , "For patients that achieve a complete response, ...
    (Date:9/17/2014)... People with facial paralysis are perceived as being less ... language of facial expression, a new study from an ... findings highlight the important role the face plays in ... against those with facial paralysis because of their disability, ... the College of Liberal Arts at Oregon State University. ...
    Breaking Medicine News(10 mins):Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:Large study reveals new genetic variants that raise risk for prostate cancer 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2Health News:Many throat cancer patients can skip neck surgery 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3
    ... for the first time that human embryonic stem cells ... mature T-cells//, raising hopes for a gene therapy to ... and the Institute for Stem Cell Biology and Medicine ... embryonic stem cells into blood-forming stem cells that in ...
    ... recent survey it was found that international nurses would need to ... NHS//. ,The step was mainly taken to give jobs ... nurses come to Britain from outside the European Union every year. ... the Philippines and Australia. The rule applies to nurses in bands ...
    ... 45 seconds, another American has a stroke, caused either by a ... minutes//, one of them will die. ,That's the bad news. ... to find and fix the problems that cause many strokes — ... ever having to open up the skull. ,New technologies, ...
    ... Dr. Bing-Huei Chen and colleagues it was found that ... form during cooking. ,The research was conduced ... Products (COPs) is produced when cholesterol-rich foods are processed ... the body cells leading to heart disease or cancer. ...
    ... California Supreme Court said that partners must inform their spouse about ... ,This came down as the court ruling in San Francisco when ... court. The wife accused the ex-husband of transmitting AIDS to her. ... decided that the spouse or partner of a person who has ...
    ... from the Korea Research Institute of Bioscience and Biotechnology//. ... found a human gene that aids in the growth and spread ... about the discovery and said that it would help in the ... was mainly conducted on mice and the research team found that ...
    Cached Medicine News:Health News:T-cells Developed from Human Embryonic Stem Cells 2Health News:Brain Surgery Without the Surgery? 2Health News:Brain Surgery Without the Surgery? 3Health News:Brain Surgery Without the Surgery? 4Health News:Brain Surgery Without the Surgery? 5Health News:Brain Surgery Without the Surgery? 6
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: